구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | CRISPR/Cas9 (CRISPR/Cas9) Allife Medical Science and Technol…·Human Papillomavirus-Related Malig… 50 trials |
|---|---|
Overview Program | CRISPR/Cas9 |
Overview Company | Allife Medical Science and Technology Co., Ltd. |
Overview Modality | CGT |
Overview Target | Human Papillomavirus-Related Malignant N |
Overview Indication | Human Papillomavirus-Related Malignant Neoplasm |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Technology Vector | retroviral therapies suppress HIV replication but fail to eliminate integrated proviral DN |
MoA Mechanism | targets with improved tissue restriction; (2) architectural innovations such as armored CARs, optimized signaling (1XX, 28-ΔIL2RB-z(YXXQ)), and cytokine-arming; (3) combinatorial antigen |
MoA Biomarker | PD-L1 therapy, reduced CD8 + T-cell infiltration, and attenuated MHC-I expression |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PK |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Biotechnological strategies to combat antibiotic resistance.. This article aims to present the current state of knowledge on four major biotechnological antimicrobial strategies and to evaluate their potential clinical applications in the context of increasing antibiotic resistance. Approaches such as phage therapy, CRISPR-Cas9 gene editing, nanoparticles, and antimicrobial peptides (AMPs) may sig… |
Clinical Safety signal | Biotechnological strategies to combat antibiotic resistance.. This article aims to present the current state of knowledge on four major biotechnological antimicrobial strategies and to evaluate their potential clinical applications in the context of increasing antibiotic resistance. Approaches such as phage therapy, CRISPR-Cas9 gene editing, nanoparticles, and antimicrobial peptides (AMPs) may sig… |
Clinical Selected reported efficacy | ORR 25% |
Clinical Reported ORR | 25.0% |
Clinical Result source | ClinicalTrials.gov NCT04035434 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT04035434 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | CRISPR/Cas9 (CRISPR/Cas9) Allife Medical Science and Technol…·Human Papillomavirus-Related Malig… 50 trials |
|---|---|
Overview Program | CRISPR/Cas9 |
Overview Company | Allife Medical Science and Technology Co., Ltd. |
Overview Modality | CGT |
Overview Target | Human Papillomavirus-Related Malignant N |
Overview Indication | Human Papillomavirus-Related Malignant Neoplasm |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Technology Vector | retroviral therapies suppress HIV replication but fail to eliminate integrated proviral DN |
MoA Mechanism | targets with improved tissue restriction; (2) architectural innovations such as armored CARs, optimized signaling (1XX, 28-ΔIL2RB-z(YXXQ)), and cytokine-arming; (3) combinatorial antigen |
MoA Biomarker | PD-L1 therapy, reduced CD8 + T-cell infiltration, and attenuated MHC-I expression |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PK |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Biotechnological strategies to combat antibiotic resistance.. This article aims to present the current state of knowledge on four major biotechnological antimicrobial strategies and to evaluate their potential clinical applications in the context of increasing antibiotic resistance. Approaches such as phage therapy, CRISPR-Cas9 gene editing, nanoparticles, and antimicrobial peptides (AMPs) may sig… |
Clinical Safety signal | Biotechnological strategies to combat antibiotic resistance.. This article aims to present the current state of knowledge on four major biotechnological antimicrobial strategies and to evaluate their potential clinical applications in the context of increasing antibiotic resistance. Approaches such as phage therapy, CRISPR-Cas9 gene editing, nanoparticles, and antimicrobial peptides (AMPs) may sig… |
Clinical Selected reported efficacy | ORR 25% |
Clinical Reported ORR | 25.0% |
Clinical Result source | ClinicalTrials.gov NCT04035434 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT04035434 |
추천 비교
추천 비교